In short
Clinical trials investigating GLYCYL-TYROSINE are studying a living donor kidney transplant setting. The trial aims to evaluate kidney function and renal reserve in both donors and recipients after transplantation. It focuses on adults in a renal transplantation programme and measures whether kidney function changes over time.
Key points
- Clinical trials investigating GLYCYL-TYROSINE are focused on a living donor kidney transplant programme. The study is in Phase 3 and is authorised. It includes both donors and recipients and follows kidney function after transplantation. The main outcome is the change in renal function, measured with plasma clearance of iohexol. The trial also measures renal reserve using an intravenous amino acid infusion. The planned enrollment is 60 people.
Trial overview
The trial titled PREDONATION RENAL RESERVE is an interventional study in a living donor renal transplantation programme. It is authorised and plans to include 60 participants.
The study is designed to evaluate the evolution of kidney function after transplant in both the donor and the recipient. The brief summary says the researchers want to understand how pre-donation kidney function and renal reserve in the donor relate to kidney function after transplantation.
Who is studied
The target population is people in a living donor kidney transplant programme. This means the trial involves both the person who donates the kidney and the person who receives it.
The source data do not list detailed age limits, sex limits, or other entry rules. Based on the trial record, the main focus is on donor-recipient pairs in renal transplantation.
What is measured
The main outcome is the change in renal function in both donor and recipient after transplantation. Renal function means how well the kidneys filter the blood and remove waste.
Kidney function is measured with a reference test called plasma clearance of iohexol. This is a standard way to check how well the kidneys clear a substance from the blood.
The trial also measures renal reserve using an intravenous infusion of an amino acid solution. Renal reserve is the kidney’s ability to increase its work when the body needs more filtering power.
The intervention listed in the record is Nephrotect solución para perfusión, given intravascularly. The trial record does not provide more detail on how this intervention is used in the study beyond its listing.
Trial design and phase
This is an interventional study, which means researchers are giving a study intervention and then measuring outcomes. The trial is in Phase 3, a later stage of clinical research that studies the question in a larger group of people.
The status is listed as Authorised. The planned enrollment is 60 participants, which suggests a focused study rather than a very large one.
What these terms mean for patients
For patients, this trial is about whether kidney function changes after a living donor transplant and whether the donor’s kidney reserve before donation helps explain those changes. The study uses measured lab-based tests instead of only symptoms or routine checks.
Because the trial record is limited, it does not tell us the final results, detailed eligibility rules, or whether the study has finished. It does show that the research is centered on donor and recipient kidney outcomes after transplantation.